Surf Wiki
Save to docs
general/h1-receptor-antagonists

From Surf Wiki (app.surf) — the open knowledge base

Carbinoxamine

Chemical compound

Chemical compound

dimethyl-ethanamine | Drugs.com = | elimination_half-life = 10 to 20 hours Carbinoxamine is an antihistamine and anticholinergic agent. It is used for hay fever, vasomotor rhinitis, mild urticaria, angioedema, dermatographism and allergic conjunctivitis. Carbinoxamine is a histamine antagonist, specifically an H1-antagonist. The maleic acid salt of the levorotatory isomer is sold as the prescription drug rotoxamine.

It was patented in 1947 and came into medical use in 1953. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. Carbinoxamine is available in various countries around the world by itself, combined with decongestants such as pseudoephedrine, and also with other ingredients including paracetamol, aspirin, and codeine.

Society and culture

In June 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older.

Brand names

Brand names include Clistin, Palgic, Rondec, Rhinopront, Ryvent.

Side effects

Continuous and/or cumulative use of anticholinergic medication, including first-generation antihistamines, is associated with a higher risk of cognitive decline and dementia in older people.

References

References

  1. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
  2. "Questions and Answers about Unapproved Drugs and FDA's Enforcement Action Against Carbinoxamine Products". U.S. Food and Drug Administration.
  3. (March 2015). "Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study". JAMA Internal Medicine.
  4. (July 2009). "Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study". Archives of Internal Medicine.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

h1-receptor-antagonists 4-chlorophenyl-compounds 2-pyridyl-compounds ethers
Want to explore this topic further?

Ask Mako anything about Carbinoxamine — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report